Innovation Rides the Crest: 2024 VBEF Future Healthcare Innovation Roadshow Successfully Concludes

To better empower the development of healthcare enterprises, gain insights into technological innovations and corporate growth trends in key sectors such as medical devices, biopharmaceuticals, and digital health, and establish a communication platform connecting enterprises with investment institutions based on needs related to financing, market entry, and partnerships.. On the morning of May 8, 2024, byVCBeatandVB100The 8th Future Medical Ecosystem Exhibition, “2024 VBEF Future Healthcare Innovation Project Roadshow,” was held at the Beijing·Beiren Yichuang International Convention and Exhibition Center.Exhibition AreaSub-venue1Successfully convened.

This Roadshow Brings TogetherCompletedTop innovative projects in the fields of medical devices, biopharmaceuticals, and digital health, showcasing their latest achievements and developments in technological innovation, product R&D, and market promotion. Rigorously selectedPosterior，Total for this instance10 High-Quality ProjectsDisplayed at the Roadshow, including multimodal tumor treatment systems, surgical robots, and intelligent rehabilitation navigation systems.

Project Pitch atHaoyue CapitalLiuHosted by Zhenzhenkicked off, and the exhibition also invited several senior commentators from the healthcare sector, includingLu Yancen, Founding Partner and CEO of Pudao Capital; Zhang Mengru, Partner at Leli Capital; Xie Da, Investment Vice President at FreeS Fund; Yuan Zhejun, General Manager of Suzhou Yihe; Hu Mingyi, Partner at Mingde Capital; Wang Yi, Partner at Legend Star; Sebright Chen, Founder and CEO of Summer Atlantic Capital, they provided in-depth commentary and engaged in discussions on the roadshow projects.

 Liu, Vice President of the Strategic Client Department at Haoyue CapitalZhenzhen

At the start of the roadshow,Mr. Su Xiaoming, Chief Strategy Officer and Vice President of Marketing at Shanghai Meijie Medical Technology Co., Ltd.Took the stage first and shared“Multimodal Tumor Treatment System” Project. He emphasized that the greatest challenge in current cancer treatment lies in recurrence and metastasis, and multimodal tumor treatment technology was developed precisely to address this issue. Spearheaded by an interdisciplinary innovation team at Shanghai Jiao Tong University, this technology originated from basic research and has been refined over more than two decades. With support from the first batch of special projects for the research and development of digital diagnostic and therapeutic equipment under the Ministry of Science and Technology during the 13th Five-Year Plan period, it combines the advantages of minimally invasive procedures and immunotherapy. While efficiently in situ inactivating tumor cells, it releases active, specific intracellular antigens, thereby stimulating the body’s own anti-tumor immune response to suppress the risk of tumor recurrence and metastasis. Su Xiaoming stated that this technology is a global first and has been marketed through the National Medical Device Innovation Green Channel. It is poised to introduce novel clinical pathways to the field of oncology through new quality productive forces driven by independent innovation, while unlocking a blue-ocean market valued at trillions.。

 Su Xiaoming, Chief Strategy Officer and Vice President of Marketing at Shanghai Meijie Medical Technology Co., Ltd.

Mr. Wang Kui, General Manager of Guangzhou Qiaojie Li Medical Technology Co., Ltd.Introduces itsCompanyR&D“Internationally Leading Endoscope-Compatible Fully Flexible Dual-Arm Surgical Robot”This surgical robot can perform the world’s smallest dual-arm surgery within the human body, with its dexterous robotic arms breaking through the current size bottleneck of mechanical arms., seamlessly compatible with existing endoscopic equipment in hospitals, providing physicians with more flexible and precise endoscopic surgical manipulation to achieve en bloc resection of tumor tissues within the gastrointestinal or urinary tract, thereby effectively treating early-stage cancer. Intuitive operation can improve surgical efficiency and quality while reducing the difficulty of physician training. The system canCompatibilityHospitalExisting endoscopy systems reduce hospitalProcurementthreshold, and plans to launch it on the market at a lower price, including hospitals in second- and third-tier cities. Currently, the product design has been finalized, with plans toHong KongConduct human clinical trials in mainland China and promote globally.

Wang Kui, General Manager of Guangzhou Qiaojeli Medical Technology Co., Ltd.

“How to Develop Drugs for ‘Undruggable Targets’ and ‘Diseases with Unknown Mechanisms’ Has Always Been a Key Challenge and Hotspot in New Drug R&D.”Mr. Li Xu, Founder of High-Dimension Medicine (Hangzhou) Co., Ltd.During the presentation, he shared his company’s experience in successfully discovering and validating multiple novel drug targets using a high-dimensional biology platform. Starting with the construction of protein–protein interaction networks, the company identifies associations between proteins to enable target substitution, thereby facilitating the rapid and accurate identification of potential targets in drug discovery and accelerating their translation into drug candidates through its mature pharmaceutical development platform. This approach is applicable to a wide range of diseases; the company has strategically built its pipeline in challenging therapeutic areas such as cancer and neurodegenerative disorders, achieving strong preclinical results. He emphasized that target selection is a critical step in innovative drug development, with first-in-class drugs targeting novel mechanisms offering substantial returns. The company is deeply committed to this field, empowering traditional drug R&D and aiming to provide novel therapeutic solutions for refractory and complex diseases.

Founder of Gaowei Medicine (Hangzhou) Co., Ltd.ConcurrentCEOLi Xu

Mr. Er Kun, Founder and Chief Product Designer of Shanghai Huicheng Scientific and Educational Instruments Co., Ltd.the speech revolves around“Pain Points in Traditional Healthcare and Systematic Digital-Intelligence Solutions” He first pointed out the numerous pain points currently facing the medical field, and then introduced a system composed of three core technologies—“brain-inspired intelligent perception models, brain-region auditory stimulation, and long-term continuous multimodal data analysis”—namely, the innovative digital-intelligence application system for physical and mental health.

This system is applied across four key domains: psychology, behavior, health, and disease. It is suitable for individuals of all age groups; in hospital settings, it can be deployed across all clinical departments. Furthermore, the system has achieved standardization and localization (compatible with domestic databases and domesticCPUs, domestically produced operating systems, and domestically produced smart wearable devices);

The advantages of this system are summarized as “comprehensive, fast, effective, cost-efficient, user-friendly, and holistic.” “Comprehensive” refers to its capacity to address a wide range of health issues; it can be termed a “pocket pharmacy” or “pocket hospital” since it is installed on mobile phones. “Fast” indicates that it is a ready-made solution capable of rapid implementation and deployment. “Effective” means it delivers quick results with no side effects. “Cost-efficient” highlights its high cost-performance ratio and low price, offering significant value for both health popularization and commercial profitability. “User-friendly” emphasizes ease of use. “Holistic” signifies that it constitutes a complete online-to-offline innovative digital-intelligent application system for physical and mental well-being. This system also aligns with the standards of new quality productive forces in healthcare.

 Er Kun, Founder and Chief Product Designer of Shanghai Huicheng Scientific and Educational Instruments Co., Ltd.

Ms. Nie Xiaoqian, R&D Director of Westlake Biopharmaceutical Science & Technology (Hangzhou) Co., Ltd.The presentation primarily focused on red blood cell-based therapeutics and their applications in the treatment of immune-related diseases and cancer.SheFirst, the unique advantages of red blood cell-based therapeutics over other cell therapies were highlighted, such as their potential for treating pan-solid tumors and their high safety profile.andIt provides a detailed explanation of how erythrocyte-based therapeutics target the human peripheral immune system to treat diseases through immunomodulatory functions, and highlights research and development directions aimed at populations resistant to immunotherapy. Furthermore,SheThe versatility and high efficiency of the red blood cell-based drug development platform were also highlighted, such as rapid process completion and compatibility with various drugs. Finally,SheShared the clinical trial progress and collaboration plans for red blood cell-based therapeutics, emphasizing their therapeutic efficacy in specific cancer types such as esophageal cancer, and outlined future R&D directions and prospects for clinical application.

Nie Xiaoqian, R&D Director of Westlake Biopharmaceutical Technology (Hangzhou) Co., Ltd.

Mr. Liu Zhenhua, Founder of Beijing Yiyue Technology Co., Ltd.The speech centered on the company’s flagship product“Shu Kang Shi” is introduced as a key product. It stems from the commercialization of major research outcomes jointly undertaken by the company and Peking University Third Hospital for the national Winter Olympics athlete support program. With clinical validation in over 4,800 cases and recognition by more than one hundred hospitals across China, it is the nation’s first integrated medical product combining assessment, prescription, and training. It has been widely applied in multiple fields, including orthopedics, sports medicine, and rehabilitation.Recently, Yi Yue Technology, in collaboration with the Institute of Sports Medicine at Peking University Third Hospital and the CAD&CG Laboratory at Zhejiang University, successfully developed the “Multimodal Radar 3D Vision Assessment-Prescription-Training Rehabilitation System,” which integrates rehabilitation assessment and training. By leveraging technologies such as artificial intelligence, digital humans, and big data, this system pioneers a new global rehabilitation model: “Exercise Prescription as Your Personal Exclusive Therapist.” The system supports the assessment of 55 disease types and the analysis of 800 medical-grade exercise parameters. Through its intelligent prescription system, patients can undergo training either within hospitals or remotely outside hospital settings, receiving dual guidance from physicians and AI while at home. Currently, “Shu Kang Shi” has become the sole benchmark for digital rehabilitation within the Huawei HarmonyOS ecosystem. In the future, the company is committed to establishing new paradigms for technological innovation and application within the industry.

Liu Zhenhua, Founder of Beijing Yiyue Technology Co., Ltd.

Mr. Lin Tailong, Chief Innovation Officer at GeneOnline & BIODND and Director of the HSC Medical System AllianceIntroduced its innovative projects“GeneOnline & BIODND—A Service Platform for Global Expansion in Life Sciences and Healthcare Technology.” This project is dedicated to providing comprehensive marketing services for the life sciences sector, including international roadshows, launch event planning, and global media operations. It has successfully hosted over 100 international matchmaking events and roadshows in multiple cities worldwide, accumulating a client base of more than 300 supporters, including collaborations with several Nobel laureates. Furthermore, Mr. Lin Tailong discussed how the company delivers end-to-end marketing solutions for the life sciences track, encompassing media placement and brand value-added services, and shared insights into the company’s global network and customer foundation. Leveraging the global debut of the BIODND Life Science Industry Information Database Platform, which utilizes AI-driven algorithms and search engine matching, the platform has already aggregated data on tens of thousands of enterprises across the life sciences industry chain. Covering markets such as the United States, Canada, Europe, Japan, South Korea, Australia, and India, it comprehensively supports companies in their successful global expansion.

 GeneOnline & BioDNDChief Innovation Officer,HSCLin Tailong, Director of the Medical System Alliance

Founder of Jiali Medical Technology (Guangzhou) Co., Ltd.&General Manager Mr. Lu ManqingIt provided a detailed introduction to the company’s novel immunotherapy project targeting advanced gastrointestinal cancers. This project is grounded in innovativeCDH17 Target: Focusing on Immunotherapy for Gastrointestinal Cancers with ARB102-ADCAntibody andcabotamig (ARB202)Dual Antibodyand other core products. The team consists of members fromMNCComposed of senior experts from large pharmaceutical companies, possessingRichR&D StrengthandClinical Research andR&D Strength. Mr. Lu Manqing also revealed that,Significant progress has been made in the R&D of the CDH17 pipeline, with sales growth projected in the coming years.

 Founder of Jiali Medical Technology (Guangzhou) Co., Ltd.&General Manager Lu Manqing

Zhongke Huisheng (Beijing) Pharmaceutical Technology Co., Ltd.Mr. Wei Shifeng, CEOIntroduction“Applications of the Nanopump Technology Platform in the Field of Drug Delivery”Project Sharing. Through a unique nanomotor shape design, this platform utilizes carbon materials derived from the dehydration of sugars and carbohydrates to achieve efficient and stable delivery of drugs, including small molecules and macromolecules such as peptides and nucleic acids. This technology not only significantly enhances drug loading capacity and therapeutic efficacy but also enables oral administration of peptides, thereby avoiding the inconvenience of injections. Furthermore, nanomotor technology demonstrates substantial potential in nucleic acid delivery, capable of efficiently deliveringmRNA delivery into cells demonstrates superior efficacy compared to existing LNP technology. Mr. Wei Shifeng’s team, leveragingIn the industryWith extensive experience, we have successfully developed multiple products with high technical barriers and plan to achieve investment returns through technology transfer, license holdings, and pharmaceutical technical services, bringing new breakthroughs to the development of the biopharmaceutical industry.

 Zhongke Huisheng (Beijing) Pharmaceutical Technology Co., Ltd.CEOWei Shifeng

Nantong Zhenle Pharmaceutical Technology Co., Ltd.Mr. Liu Xiaoxi, CEObrought by“Project on Innovative Drugs Focusing on Advanced Drug Delivery Systems” Sharing: This project utilizes platelets as carriers to precisely deliver macromolecular drugs, such as PD-1 inhibitors, to tumor sites via conjugation technology, thereby achieving targeted therapy. The unique advantage of this approach lies in the fact that platelets are the only cells in the body capable of self-fragmentation into granules, enabling complete drug release at the target site to maximize therapeutic efficacy while minimizing side effects. Furthermore, platelet-mediated targeted delivery enhances drug bioavailability and shortens the onset time of action, offering new solutions for the treatment of cancer and other major diseases.。

Nantong Zhenle Pharmaceutical Technology Co., Ltd.CEOLiu Xiaoxi

Following the conclusion of the ten roadshow projects, byFounding Partner of Pudao Capital,Mr. Lu Yancen, CEO, served as the moderator, joined by Mr. Zhang Mengru, Partner at Le Li Capital; Mr. Xie Da, Vice President of Investment at FreeS Fund; Mr. Yuan Zhejun, General Manager of Suzhou Yihe; and Mr. Hu Mingyi, Partner at Mingde Capital.Together, Let's Begin“A New Era in Healthcare Venture Capital: Technology-Driven, Innovation-Led, and Powered by Youth” Roundtable DiscussionGuests shared their perspectives on the development trends of the new era in healthcare venture capital.

Mr. Zhang MengruHe emphasized the importance of domestic substitution in the medical device sector, noting that this trend holds significant implications for reducing treatment costs and enhancing primary healthcare coverage. He believes that over the next decade, China’s engineer dividend and technological accumulation will create substantial development opportunities in the medical equipment field.Mr. Xie DaFrom an investment perspective, he analyzed the trends in medical technology innovation and globalization. He highlighted the importance of pricing autonomy and innovative value for novel drugs, and predicted that China will gradually emerge as a global center for research and development (R&D) and innovation. Meanwhile, he also emphasized the importance of improving healthcare service efficiency and accelerating the iteration of innovative technologies.Mr. Yuan ZhejunHe shared his insights on biopharmaceutical investment, pointing out that accelerated technological innovation, upgraded market demand, and shifts in policy direction are the primary transformations currently reshaping the healthcare investment landscape. He emphasized the challenges companies face in terms of capitalization pathways, cash flow management, and global expansion capabilities, and advised that innovative drug companies should possess fundamental self-sustaining revenue-generating capabilities.Mr. Hu MingyiThe discussion addressed the importance of overseas expansion and global strategic layout, with his view that outstanding enterprises will have the opportunity to stand out in the current economic environment. He also highlighted the significance of early-stage innovation, as well as developments in brain science, small nucleic acids, andHigh interest in cutting-edge technologies such as AI-driven drug discovery.Mr. Lu YancenSummaryHe discussed the industry cycle and the real-world challenges of the capital market, advising startups to focus on technological innovation and clinical data advantages while emphasizing the importance of cash flow. He also mentioned the trends of globalization and de-globalization, as well as Chinese enterprises inThe Potential of AI in Drug Development. Finally, the panelists agreed that despite numerous real-world challenges, the healthcare venture capital sector remains full of opportunities, especially for companies that can continuously innovate and adapt to change.